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NOTCH1 inhibition in vivo results in mammary
tumor regression and reduced mammary
tumorsphere-forming activity in vitro
Matthew J Simmons1, Ryan Serra2, Nicole Hermance1 and Michelle A Kelliher1*
Abstract
Introduction: NOTCH activation has been recently implicated in human breast cancers, associated with a poor
prognosis, and tumor-initiating cells are hypothesized to mediate resistance to treatment and disease relapse. To
address the role of NOTCH1 in mammary gland development, transformation, and mammary tumor-initiating cell
activity, we developed a doxycycline-regulated mouse model of NOTCH1-mediated mammary transformation.
Methods: Mammary gland development was analyzed by using whole-mount analysis and by flow cytometry in
nulliparous transgenic mice maintained in the presence/absence of doxycycline (or intracellular NOTCH1).
Mammary tumors were examined histologically and immunophenotyped by staining with antibodies followed by
flow cytometry. Tumors were transplanted into mammary fat pads under limiting dilution conditions, and tumor-
initiating cell frequency was calculated. Mammary tumor cells were also plated in vitro in a tumorsphere assay in
the presence/absence of doxycycline. RNA was isolated from mammary tumor cell lines cultured in the presence/
absence of doxycycline and used for gene-expression profiling with Affymetrix mouse arrays. NOTCH1-regulated
genes were identified and validated by using quantitative real-time polymerase chain reaction (PCR). Mammary
tumor-bearing mice were treated with doxycycline to suppress NOTCH1 expression, and disease recurrence was
monitored.
Results: Similar to published studies, we show that constitutive expression of human intracellular NOTCH1 in the
developing mouse mammary gland inhibits side branching and promotes luminal cell fate. These mice develop
mammary adenocarcinomas that express cytokeratin (CK) 8/18. In vivo limiting-dilution analyses revealed that these
mammary tumors exhibit functional heterogeneity and harbor a rare (1/2,978) mammary tumor-initiating cell
population. With this dox-regulated NOTCH1 mammary tumor model, we demonstrate that NOTCH1 inhibition
results in mammary tumor regression in vivo and prevents disease recurrence in four of six tumors tested.
Consistent with the in vivo data, NOTCH1 inhibition reduces mammary tumorsphere activity in vitro. We also
identify the embryonic stem cell transcription factor Nanog as a novel NOTCH1-regulated gene in tumorspheres
and in mouse and human breast cancer cell lines.
Conclusions: These data indicate that NOTCH1 inhibition results in mammary tumor regression in vivo and
interferes with disease recurrence. We demonstrate that NOTCH1-transformed mouse mammary tumors harbor a
rare mammary tumor-initiating population and that NOTCH1 contributes to mammary tumor-initiating activity. This
work raises the possibility that NOTCH therapeutics may target mammary tumor-initiating cells in certain human
breast cancer subtypes.
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Introduction
NOTCH activation has been implicated in several malig-
nancies; notably T-cell acute lymphoblastic leukemia,
chronic lymphocytic leukemia, glioblastoma, and breast
cancer [1-11]. Overexpression of NOTCH receptors has
been implicated in ductal carcinoma in situ (DCIS) and
invasive breast cancer [12,13], and high levels of the
NOTCH ligand JAG1 appear to predict a poor overall sur-
vival [14]. High NOTCH1-receptor levels have been linked
with basal-like, triple-negative (estrogen receptor-, proges-
terone receptor-, and HER2-negative) breast cancer, and
NOTCH1 levels correlate with abbreviated survival [15].
More recently, silencing of Lunatic Fringe, the glycosylase
that regulates NOTCH1 ligand activity, has been observed
in patients with basal-like breast cancer, and increased
levels of intracellular NOTCH1 are detected in these
patients’ cells [16]. NOTCH1 activity levels have also been
shown to correlate with the development of resistance to
conventional as well as to targeted therapies [17-20], lead-
ing us to hypothesize that NOTCH1 may contribute to
therapeutic resistance and disease recurrence by regulating
breast tumor-initiating cell activity.
NOTCH pathway activation is triggered on ligand-
receptor interaction. Mammals possess four NOTCH
receptors (NOTCH 1-4) and five ligands (JAG1, 2,
DELTA-like (DLL) 1, 3, and 4). Ligand binding stimulates
two sequential proteolytic cleavages; the first in the extra-
cellular domain mediated by metalloproteases of the
ADAM family, and the second within the transmembrane
domain mediated by the gamma-secretase complex. The
second cleavage allows the release and translocation of
the intracellular domain of NOTCH into the nucleus,
where it associates with the CBF1/RBP-J/Suppressor of
Hairless/LAG-1 (CSL) repressor and on the recruitment
of co-activators Mastermind-like 1 (MAML1) and CBP/
p300 induces expression of NOTCH target genes, includ-
ing HES1, HEY2, DELTEX1, and c-MYC [21]. Gamma
secretase inhibitors (GSIs) have been shown to inhibit
Notch1 and to have antileukemia activity in vivo [22-24].
Constitutive Notch1 signaling in the normal mouse
mammary stem cell (MaSC) has been shown to stimulate
differentiation toward a luminal fate, whereas suppression
of Notch signaling in MaSC via CSL knockdown results in
the expansion of the MaSC compartment [25,26]. These
studies implicate Notch1 pathway activation in mouse
luminal progenitor expansion and differentiation. NOTCH
pathway activation has also been shown to enhance
human mammosphere formation, which likely reflects
NOTCH pathway effects on the human mammary stem
or progenitor cells [27].
In addition to the Notch receptor family, the gamma-
secretase complex regulates the expression of ErbB4,
CD44, and E cadherin, cell-surface receptors known to
contribute to tumor growth, migration, and invasion
[28-30]. Thus, experiments that use GSIs to determine
the effect(s) of Notch inhibition on tumor growth likely
affect the stability of other substrates relevant to mam-
mary gland transformation. Moreover, GSI studies fail to
reveal which Notch receptor family member mediates the
effects on tumor growth/survival.
To determine the specific effects of NOTCH1 activa-
tion/inhibition on bulk mammary tumor growth and on
mammary tumor-initiating cells, we generated a mouse
mammary tumor model in which human intracellular
NOTCH1 expression is doxycycline regulated. Consistent
with previous reports [25,26,31-33], we demonstrated
that NOTCH1 signaling stimulates luminal cell fate and
results in luminal lineage transformation. In vivo limit-
ing-dilution analysis reveals that only a small percentage
(~1/3,000) of NOTCH1-driven mammary tumor cells are
capable of transplanting disease, revealing that mammary
tumor-initiating cells contribute to disease pathogenesis
in this model. We also demonstrated that NOTCH1 sig-
naling is required for mammary tumor-initiating cell
activity, as NOTCH1 inhibition results in rapid mam-
mary tumor regression and delays and, in some cases,
prevents disease recurrence. By using gene-expression
profiling, we identified the embryonic stem cell transcrip-
tion factor Nanog as a novel NOTCH1-regulated gene in
mammary tumor cells. These data demonstrate that
NOTCH1 activation stimulate luminal lineage develop-
ment and implicate NOTCH1 in the regulation of mam-
mary tumor-initiating activity.
Materials and methods
Mice histopathology and immunohistochemistry
The MMTV-tTA (C57BL/6) and tet-op-NotchIC (FVB/N)
mice were described previously [34,35] and generously
provided by D. Tenen and A.J. Capobianco, respectively.
Mice were maintained in mating pairs of MMTV-tTA/
TOP-ICN1 females and MMTV-tTA males, and females
were monitored weekly for signs of disease. Mice were
killed when total tumor volume surpassed 1,000 mm3, as
determined by external measurement by using calipers.
Tumors were fixed in 10% formalin for 4 hours at room
temperature or overnight at 4°C, then transferred to 70%
ethanol and maintained at 4°C until mounting in paraffin
and sectioning. Sections were stained with antibodies
against mouse keratin 5 (PRB-160P; Covance, Princeton,
NJ), keratin 8/18 (GP11; Progen Biotechnik, Heidelberg,
Germany), keratin 14 (Clone LL002; Thermo Scientific,
Waltham, MA) or estrogen-receptor alpha (sc-8005; Santa
Cruz Biotechnology, Santa Cruz, CA). All animal experi-
ments were reviewed and approved by the Institutional
Animal Care and Use Committee (IACUC) of the Univer-
sity of Massachusetts Medical School.
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Establishment of tumor-derived cell lines
Primary mouse mammary tumors were minced with a
razor blade and digested in DMEM/F12 (1:1) media sup-
plemented with 5% fetal bovine serum (FBS) and 2 mg/ml
collagenase (Gibco, Grand Island, NY) for 2 hours at 37°C.
Samples were spun down and washed 5 times in PBS sup-
plemented with 5% FBS and then plated onto 10-cm
collagen-coated plates (BD Biosciences, San Diego, CA) in
DMEM/F12 (1:1) media supplemented with 2% FBS and
penicillin/streptomycin. Cell clusters were left undisturbed
for 3 days, with subsequent media changes every 3 days,
gradually increasing FBS concentration to 10%. When
confluent, cells were passaged at a 1:2 or 1:3 dilutions after
a 5-minute incubation with Versene (Gibco, Grand Island,
NY) and maintained on standard tissue-culture plates.
Mammary fat-pad transplants
For limiting-dilution studies, primary mammary tumors
were digested as previously described [36,37]. In brief,
tumors were sequentially digested at 37°C in 300 U/ml
collagenase (Gibco, Grand Island, NY) plus 100 U/ml
hyaluronidase (Sigma, St. Louis, MO) (2 hours), 0.25%
trypsin (Gibco, Grand Island, NY) (2 minutes), and 5 mg/
ml Dispase II (Roche, Indianapolis, IN) plus 0.1 mg/ml
DNaseI (Sigma, St. Louis, MO) (5 minutes). Cells were
filtered through a 40-μm mesh, counted, and enzymatic
digestion was repeated until the suspension was >95%
single cells. Serial dilutions were resuspended in 35 μl
gelatinous protein mixture (Matrigel; BD Biosciences,
San Diego, CA) and injected into the thoracic mammary
fat pads of nude mice. For tumor-derived cell-line tumor-
igenicity assays, cultured cells were lifted by using Ver-
sene (Gibco, Grand Island, NY), followed by trypsin-
EDTA treatment and filtering through a 40-μm mesh.
Approximately 106 cells were resuspended in 35 μl
Matrigel and injected into the thoracic mammary fat
pads of nude mice.
Tumorsphere cultures
Single-cell suspensions (>95% single cells) were generated
from primary mammary tumors as described earlier. Cells
were then plated in 3 ml defined tumorsphere media [38]
plus 0.5% methylcellulose (R&D Systems, Minneapolis,
MN) per well of a six-well ultra-low-attachment plate
(Fisher Scientific, Pittsburgh, PA), at a concentration of
20,000 cells/ml. For doxycycline-treated samples, 2 μg/ml
doxycycline was added to the culture media at the time of
plating.
Flow cytometry
Tumor samples, thoracic and inguinal mammary fat pads
from nulliparous females, or tumor-derived cell lines
were subjected to enzymatic digestion to create a single-
cell suspension as described earlier. Antibodies against
mouse antigens were purchased from BD Pharmingen
(San Diego, CA) unless otherwise noted, and included
Ter-119-PE, CD31-PE, CD45R-PE, CD61-FITC, CD24-
biotin, streptavidin-APC, and CD29-PE-Cy7 (eBioscience,
San Diego, CA). Cells were stained in PBS at 4°C for 25
minutes and analyzed live. For cell-cycle analysis, cells
were fixed in 70% ethanol, stained with propidium iodide
(PI), and analyzed for DNA content.
Microarray analysis
Tumor-derived cell lines 8534 and 8542 were left
untreated or treated with 2 μg/ml doxycycline for 24
hours. Cells were collected by scraping, and total RNA
was isolated by using Trizol (Invitrogen, Grand Island,
NY). After real-time PCR validation of NOTCH1 target-
gene modulation, RNA samples were further purified by
using the RNAeasy Mini kit (Qiagen, Valencia, CA) and
hybridized to Affymetrix mouse genome 430A2.0 arrays
(Affymetrix, Santa Clara, CA, USA). Raw data were pro-
cessed with MAS5 analysis, and genes showing a >2.0-fold
change in both cell lines were considered targets of inter-
est. The data from these arrays have been deposited in the
NCBI Gene Expression Omnibus and are accessible
through GEO Series accession number GSE34146.
Quantitative RT-PCR
Total RNA from cells was extracted by using Trizol
(Invitrogen, Grand Island, NY). cDNA was prepared
with the Superscript First Strand Synthesis kit (Invitro-
gen, Grand Island, NY), and PCR was carried out with
SYBR Green (Qiagen, Valencia, CA). The following pri-
mers were used in this study: hey1, 5 -TGAGCTGA-
GAAGGCTGGTAC-3 (Forward) and 5 -ACCCCAAAC
TCCGATAGTCC-3 (Reverse); deltex1, 5 -TGCCTGGT
GGCCATGTACT (Forward) and 5 -GACACTGCA
GGCTGCCATC-3 (Reverse); b-actin, 5 -CGAGGCCCA-
GAGCAAGAGAG-3 (Forward) and 5 -CGGTTGGCC
TTAGGGTTCAG-3 (Reverse); c-myc, 5 -CTGTTTGAA
GGCTGGATTTCCT-3 (Forward) and 5 -GTCGTGGC
TGTCTGCGG-3 (Reverse); hes1, 5 -AAGACGGCCTCT
GAGCACA-3 (Forward) and 5 -CCTTCGCCTCTT
CTCCATGAT-3 (Reverse); nanog, 5 -TCTTCCTGGT
CCCCACAGTTT-3 (Forward) and 5 -GCAAGAA-
TAGTTCTCGGGATGAA-3 (Reverse). The nanog pri-
mer set (PrimerBank ID 31338864a1) was obtained from
PrimerBank [39].
Western blotting
Protein was isolated from cells collected by using Versene,
washed in PBS, and lysed in radioimmunoprecipitation
assay (RIPA) buffer containing protease inhibitor tablets
(Roche, Indianapolis, IN). Fifteen to twenty-five micro-
grams of total protein was resolved via 9% sodium dode-
cylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE),
Simmons et al. Breast Cancer Research 2012, 14:R126
http://breast-cancer-research.com/content/14/5/R126
Page 3 of 17
as previously described [40]. Blots were probed with
antibodies against intracellular NOTCH1 (provided by Jon
Aster), active NOTCH1 (2421; Cell Signaling Technology,
Danvers, MA), Nanog (AB9220; Millipore, Billerica, MA),
cytokeratin 8/18 (GP11; Progen Biotechnik, Heidelberg,
Germany), caspase-3 (Cell Signaling, Danvers, MA), and
a-tubulin (T5168; Sigma, St. Louis, MO) or Erk1/2 (Cell
Signaling, Danvers, MA) to control for equal loading. For
MDA-MB-231 study, cells were left untreated or treated
with the gamma-secretase inhibitor (GSI) Compound E
(Axxora, Farmingdale, NY) at 10 μM for the times noted,
before cells were collected, and analyzed as described
earlier.
Mammary fat pad whole mounting
Inguinal fat pads were isolated from mice administered
doxycycline-treated sugar water (10 μg/ml) for various
time periods, spread on glass slides, and fixed in glacial
acetic acid/ethanol (1:3) overnight. Samples were washed
in 70% ethanol for 15 minutes, rinsed in distilled water
for 5 minutes, and stained overnight in carmine alum
solution. Samples were then dehydrated and transferred
to xylene overnight for delipidation. Whole mounts
were briefly air dried, and coverslips were mounted by
using Permount (Fisher Scientific, Pittsburgh, PA).
MTT assay
MTT cell-viability assays were performed as previously
described [22], with the following modifications. In
brief, approximately 104 cells/200 μl of a cell suspension
were plated in a 96-well flat-bottom plate, ~16 hours
before treatment. Cells were then left untreated or trea-
ted with 2 μg/ml doxycycline. After 72 hours, 20 μl of a
5-mg/ml 3-(4,5-dimethylthiazol-2-y1)-2,5-diphenyl tetra-
zolium bromide (MTT) solution (Sigma-Aldrich, St.
Louis, MO) was added and incubated for 4 hours at 37°
C. Media was then removed, and the reagent was solubi-
lized with 100 μl dimethyl sulfoxide (DMSO) (Sigma-
Aldrich, St. Louis, MO) and incubated for 10 minutes at
room temperature. Plates were then analyzed at A595
wavelength. Data are plotted as absorbance and are the
average of five independent experiments. The P values
were calculated by using a two-tailed distribution and
paired Student t test.
Tumorsphere immunofluorescence
For detection of Keratin 8/18 and Nanog protein expres-
sion, primary mammary tumor cells were grown under
mammosphere culture conditions for 7 days. Spheres
were collected by pipette under a dissection microscope,
pooled, washed, and digested in 0.25% trypsin (Gibco,
Grand Island, NY) at 37°C for 5 minutes, and the result-
ing cell suspension was cytospun onto coverslips. In par-
allel, tumor-derived cell line 8542 was plated onto glass
coverslips and allowed to grow for 48 hours before pro-
cessing. Cell line and primary samples were fixed in 4%
paraformaldehyde and permeabilized for 10 minutes in
phosphate-buffered saline (PBS) containing 0.2% Triton
X-100. Cells were washed with PBS containing 0.02%
Triton X-100 and 10% FBS, followed by incubation with
a-Keratin 8/18 (Progen Biotechnik, Heidelberg, Ger-
many) and a-Nanog (Millipore, Billerica, MA) antibo-
dies or IgG controls (Santa Cruz, Santa Cruz, CA) for 1
hour at room temperature. Cells were stained with
FITC- or rhodamine-conjugated secondary antibodies
(Santa Cruz, Santa Cruz, CA), and coverslips were
mounted with Permount (Fischer Scientific, Pittsburgh,
PA) and photographed under ultraviolet illumination at
a magnification of 600X.
For detection of cell-surface marker CD61, tumor-
spheres were grown, collected, and digested with trypsin
as described earlier to break up the spheres into loose
aggregates of cells. Cells were resuspended in PBS plus 5%
FBS and stained with CD61-FITC (1:75, eBioscience, San
Diego, CA) or IgG-FITC at 4°C for 1 hour in the dark, and
washed. Cells were then cytospun onto glass coverslips
and mounted with DAPI-containing mounting medium
and photographed under ultraviolet illumination at a mag-
nification of 600X.
Results
NOTCH1 expression impairs ductal side branching and
expands the mature luminal population
To investigate the role of NOTCH1 in mammary gland
development and tumor progression, we mated mice
expressing the human intracellular form of NOTCH1
under control of a tet-responsive promoter (Tet-Op-
ICN1) with mice expressing the tet Transactivator under
control of the MMTV promoter (MMTV-tTA) [34,41],
allowing us to modulate expression of intracellular
NOTCH1 in the developing mouse mammary gland. In
the absence of doxycycline, these mice express intracellu-
lar NOTCH1, whereas addition of doxycycline to the
drinking water suppresses NOTCH1 expression. Consis-
tent with similar models [31-33], MMTV-tTA/TOP-ICN1
female mice appear normal at birth, and transgenic
females had fully functional mammary glands capable of
nursing their young. Whole-mount analysis of the mam-
mary fat pad of 8- to 12-week-old nulliparous females
revealed decreased ductal side branching in developing
transgenic mammary fat pads compared with that in wild-
type littermate controls (Figure 1A). Doxycycline adminis-
tration suppressed intracellular NOTCH1 expression
(see Additional file 1) and reversed this phenotype, with
dox-treated mice exhibiting decreased side branching com-
pared with untreated transgenic littermates (Figure 1A).
Notch signaling is critical for proper mammary lineage
specification and differentiation. Suppression of Notch
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signaling in the mammary epithelium of Rbp-Jfl/fl;
MMTV-Cre mice, or knockdown of Cbf-1 in sorted
mammary stem cells (MaSCs), leads to a block in mam-
mary differentiation, resulting in the expansion of the
MaSC population [25,26]. Conversely, constitutive
Notch1 activation promotes luminal cell commitment,
at the expense of the myoepithelial population, and con-
fers self-renewal capacity on luminal progenitor cells in
Matrigel assays [25].
To examine further the effects of NOTCH1 activity on
mammary developmental fate and transformation, we
stained cells isolated from the developing mammary
gland with antibodies to surface markers and analyzed
with flow cytometry. Published studies have shown that
expression of CD29 (b1-integrin) and CD24 (heat-stable
antigen) can be used to distinguish the luminal cell
population (lin-CD29loCD24+) from the combined mam-
mary stem cell and basal cell subpopulations (lin-
CD29hiCD24+). Analysis of the mammary fat pad of the
premalignant MMTV-tTA/TOP-ICN1 mouse revealed a
slightly expanded luminal cell population compared
with wild-type littermates (average 22.5% versus 15.7%;
SEM, 2.29% versus 1.09%; n = 5) (Figure 1B, top panels).
Further separation of the luminal population into lumi-
nal progenitors and mature luminal cells on the basis of
CD61 expression levels [42] reveals an average 47%
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Figure 1 Notch1 expression impairs ductal side branching and stimulates luminal differentiation. (A) NOTCH1 inhibits mammary gland
branching morphogenesis. Representative (n = 3) whole-mount analysis of mammary fat pads from wild-type, premalignant 3-month-old MMTV-
tTA/Tet-Op-NOTCH1 or MMTV-tTA/Tet-Op-NOTCH1 mice treated with doxycycline for 7 days. Scale bars, 1,000 μm. (B) Constitutive NOTCH1
signaling promotes luminal differentiation. Matching fluorescence-activated cell sorting (FACS) histograms of mammary epithelial cells derived
from the mice described in A. Cells were stained with antibodies against Ter119, CD45, and CD31, and the lineage-negative cells were then
stained with CD29 and CD24 (top), and CD61 antibodies (bottom) and analyzed with flow cytometry. Dashed line, staining with an isotype-
matched control.
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(SEM 10.4%, n = 5; P < 0.05) decrease in the proportion
of CD61+ cells in mice expressing intracellular NOTCH1
(Figure 1B, bottom panels). Treatment of a premalignant
MMTV-tTA/TOP-ICN1 littermate with doxycycline for
7 days before analysis results in a decrease in the relative
proportion of luminal cells to levels comparable to those
observed in control littermates. A shift in CD61 expres-
sion is also observed in the dox-treated mice, revealing a
decrease in mature luminal cells and a corresponding
increase in luminal progenitors (Figure 1B, top and bot-
tom panels). The decrease in the frequency of CD61+
luminal progenitors in the NOTCH1 transgenic mice
was not due to NOTCH1 effects on CD61 mRNA levels
(see Additional file 2).
The change in the percentage of luminal progenitors
was highly reproducible in the five experiments performed,
and the data were statistically significant (P < 0.05). The
decreased frequency resulted in modest decreases in the
absolute number of luminal progenitors in the NOTCH1
transgenic mammary gland (37,167 ± 6,406 SEM com-
pared with wt control, 43,159 ± 5,643 SEM; n = 3 mice of
each genotype); however, this decrease in luminal progeni-
tor numbers was not manifest in statistically significant
differences in colony-forming activity in vitro (data not
shown). Collectively these data are consistent with other
reports [25,26] that suggest that Notch1 promotes a lumi-
nal cell fate, and that the majority of these cells are fully
differentiated in the premalignant gland.
NOTCH1 expression results in mammary gland
transformation
Previous Notch-driven mammary-tumor mouse models
display varying phenotypes, ranging from mammary
hyperplasia and DCIS in nulliparous mice to lactation-
dependent regressing tumors and nonregressing invasive
adenocarinomas [8,31-33]. To identify the target cell of
NOTCH1-mediated transformation, we monitored a
cohort of MMTV-tTA/TOP-ICN1 transgenic females
and their wild-type littermates for disease development.
Consistent with the MMTV expression in T cells and
the demonstrated role of Notch1 as a T-ALL oncogene
[4,5,40], 18% of the transgenic mice developed T-ALL-
like disease and were excluded from this study (data not
shown). The remaining cohort maintained under mating
conditions developed mammary adenocarcinomas by 12
months of age, with a median tumor-free survival of 225
days and a penetrance of >90% (Figure 2A). Nulliparous
females also developed mammary tumors with reduced
penetrance and after an average latency of 353 days (see
Additional file 3). Some mice displayed tumors in multi-
ple mammary glands, although the majority (59%) of
mice had a single mammary tumor.
Multiple, focal tumor initiations were observed within
a single fat pad, composed of intertwining cords of
neoplastic cells forming tubules two or three cells wide
(Figure 2B). These strands are further delineated by a
fibrovascular stroma, and some strands appear to con-
tain a third cell population resembling myoepithelium.
Some tumors also exhibited microcalcification and infil-
trated the adjacent skeletal muscle (data not shown).
The tumor cells displayed large nuclei with sparse
cytoplasm and had a low mitotic rate.
Recent studies suggest that deregulated NOTCH1
signaling may contribute to relapse and/or chemothera-
peutic resistance in triple-negative basal-like breast can-
cers, and that NOTCH signaling may be required to
maintain ER-negative tumors [15,18,20]. Consistent with
these findings and other mouse mammary tumor mod-
els, immunohistochemical analysis failed to detect ERa
expression in these NOTCH1-induced mouse mammary
tumors, whereas ERa reactivity was observed in the
luminal cells of the wild-type mammary fat pad, as
expected (Figure 2C, top panels). Keratin 14 (K14) is
expressed in basal cells in the mouse mammary epithe-
lium [43], and importantly, K14 is expressed by human
and mouse mammary stem cell populations [44-46].
Immunohistochemical analysis of tumor sections with
antibodies against Cytokeratins K8/18, K5, and K14
revealed that the NOTCH1-induced mammary tumors
consist of K8/18-expressing cells, confirming that the
tumor consists of primarily luminal epithelial cells (Fig-
ure 2C, middle right panel). Many tumors also con-
tained rare cells (<1%) that stained positive for K14 or
K5 (Figure 2C, right middle and bottom panel).
NOTCH1 inhibition induces apoptosis of mouse mammary
tumor cell lines
Primary mouse and human T-ALL cells are sensitive to
the effects of Notch1 inhibition and undergo G1 arrest
and/or apoptosis [4,5]. To determine whether mammary
tumor growth/survival remains NOTCH1 dependent, we
established cell lines from primary MMTV-tTA/TOP-
ICN1 mammary tumors. Each cell line retained doxycy-
cline responsiveness, as treatment with dox for 24 hours
resulted in decreased ICN1 expression compared with
untreated controls (Figure 3A). Consistent with tumor
immunohistochemistry data, all four mammary tumor-
derived cell lines expressed cytokeratin 8/18 (Figure 3B).
Interestingly, the mammary tumor cell lines also
expressed the basal markers K14 and/or K5 (Figure 3B),
indicating that conversion to culture may select for a
rare, double-positive mammary tumor cell. Transplanta-
tion of these mammary tumor cell lines into nude mice
resulted in growth of mammary tumors that appeared
histologically identical to primary tumors (see Addi-
tional file 4).
To determine the consequences of NOTCH1 inhibi-
tion on mammary tumor growth/survival, we treated the
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mammary tumor cell lines with doxycycline for 72 hours
and performed an MTT analysis. Doxycycline treatment
resulted in >50% (P < 0.05) decrease in mammary
tumor cell viability (Figure 3C). Cell-cycle analysis of
the doxycycline-treated mammary tumor cell lines
revealed increases in the sub-G1 population, with little
to no evidence of cell-cycle arrest (Figure 3D). Consis-
tent with these results, cleaved (active) caspase 3 was
detected in two of three doxycycline-treated mammary
tumor cell lines examined (Figure 3E). These studies
reveal that a sustained NOTCH1 signal is required for
the maintenance of the mammary tumor cell lines.
NOTCH1 activation in mammary tumor cells induces
Nanog expression
Previous studies have demonstrated the importance of
c-Myc as a Notch1-regulated gene in T-ALL [40,47,48]
and in mouse mammary tumorigenesis [32]. To identify
novel NOTCH1-regulated genes important in mouse
mammary tumorigenesis, we performed a microarray
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Figure 2 Deregulated NOTCH1 expression results in mammary gland transformation. (A) Constitutive NOTCH1 signaling results in
mammary tumor formation. A cohort of wild-type (n = 15) and MMTV-tTA/TOP-ICN1 (n = 65) mice were maintained under mating conditions
and monitored for tumor formation. The proportion of tumor-free mice was plotted by using the Kaplan-Meier software. (B) NOTCH1 expression
leads to tubular adenocarcinomas. Sections from MMTV-tTA/TOP-ICN1 primary mammary tumors were fixed in 10% formalin, paraffin embedded,
sectioned, and stained with hematoxylin and eosin (H&E). Analysis of tumors showed multiple initiations within a single fat pad, with cordlike
structures of two or three cell layers separated by stroma. Scale bars, 100 μm. (C) NOTCH1-transformed mammary tumors are ERa-negative and
express the luminal lineage cytokeratins 8 and 18. Tumor sections from wild-type mammary fat pad (left) or primary tumor (right) were stained
with antibodies against ERa (top), Cytokeratin 8/18 and Cytokeratin 5 (middle), or Cytokeratin 14, and counterstained with DAPI (bottom). Scale
bars, 100 μm.
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analysis on untreated and doxycycline-treated mammary
tumor cell lines (GEO accession number GSE34146). In
addition to decreased expression of known NOTCH1-
regulated genes, such as Hes1, Deltex1, Hey1, and c-
Myc, suppression of NOTCH1 signaling resulted in a
ninefold (P < 0.005) decrease in the expression of
Nanog, a transcription factor required for the mainte-
nance of embryonic stem (ES) cell pluripotency [49-51].
We validated this finding in multiple NOTCH1-trans-
formed mammary tumor cell lines using quantitative real-
time PCR and observed on average a fivefold decrease in
Nanog mRNA levels in doxycycline-treated mammary
tumor cells (Figure 4A). Decreased Nanog protein levels
were also observed in doxycycline-treated mammary
tumor cultures and correlated with decreased ICN1
expression (Figure 4B). We were, however, unable to
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Figure 3 NOTCH1 inhibition induces apoptosis of mammary tumor cells. (A) NOTCH1 expression is rapidly suppressed in doxycycline-
treated mammary tumor cell lines. Cell lines were left untreated or treated with doxycycline (2 μg/ml) for 24 hours, and lysates were analyzed
for ICN1 expression with immunoblotting. A doxycycline-regulated T-ALL cell line 3404 is included as a control. (B) Mammary tumor cell lines
express cytokeratin 8/18, but have variable expression of basal cytokeratins 5 and 14. Cell-line lysates were analyzed for CK8/18, CK5, and CK14
expression with immunoblotting. (C) NOTCH1 inhibition arrests mammary tumor cell growth. Three mammary tumor cell lines (8066, 8534, and
8542) and T-ALL cell line 3404 were left untreated or treated with doxycycline (2 μg/ml) for 72 hours, and cell growth was measured by using
an MTT assay. The figure represents the average of three independent experiments, statistically analyzed by the Student paired t test.
(D) NOTCH1 inhibition induces apoptosis of multiple mammary tumor cell lines. Tumor-derived cell lines 8066, 8534, and 8542 were treated with
2 μg/ml doxycycline or left untreated for 0, 24, or 72 hours. Cells were assayed for DNA content by staining with PI followed by flow cytometry.
(E) NOTCH1 inhibition results in caspase 3 activation. Cells were left untreated or treated with doxycycline (2 μg/ml) for 72 hours, and lysates
were analyzed for cleaved or total caspase-3 levels with immunoblotting.
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Figure 4 NOTCH1 regulates Nanog expression in mouse mammary tumor cells. (A) Nanog expression is suppressed on NOTCH1 inhibition.
RNA was harvested from tumor cell lines left untreated or treated with doxycycline (2 μg/ml) for 24 hours and c-Myc, Hes1, Deltex1, Hey1, and
Nanog expression levels determined with quantitative real-time PCR. Expression is normalized to the untreated control. (B) Doxycycline treatment
reduces Nanog protein levels. The mouse mammary tumor lines (8542, 8526) were left untreated or treated with doxycycline (2 μg/ml) for the time
periods indicated. Lysates were analyzed for ICN1 and Nanog expression with immunoblotting, and relative band intensities were quantified.
(C, D) Nanog is expressed in the nuclei of NOTCH1-transformed mouse mammary tumor cell lines and primary tumorspheres. The mouse
mammary tumor cell line 8542 was grown on coverslips, and primary tumorspheres were dissociated and centrifuged onto slides, followed by
fixation in 4% paraformaldehyde. The cells were then permeabilized with Triton X-100 and immunostained by using antibodies against cytokeratin
8/18 (red) or Nanog (green). Cells were photographed at 400 × magnification. Scale bars, 100 μm. (E) NOTCH1 regulates NANOG expression in
human breast cancer cells. The human basal-like breast cancer cell line MDA-MB-231 was left untreated or treated with the g-secretase inhibitor
Compound E (10 μM) for the time periods indicated, and intracellular NOTCH1 and NANOG expression levels examined with immunoblotting.
Simmons et al. Breast Cancer Research 2012, 14:R126
http://breast-cancer-research.com/content/14/5/R126
Page 9 of 17
detect Nanog expression in primary NOTCH1-trans-
formed mammary tumors by using immunohistochemistry
or quantitative real-time PCR (not shown). We hypothe-
size that Nanog expression may be limited to a subset of
tumor cells and therefore plated primary tumors under
tumorsphere conditions to select for mammary tumor-
initiating cells. Nanog expression was detected in the
nuclei of NOTCH1-transformed mammary tumor cell
lines and in primary tumorspheres (Figure 4C, D).
To determine whether NOTCH1 contributes to the
regulation of NANOG in human breast cancer cells, we
treated the basal-like human breast cancer cell line
MDA-MB-231 with the g-secretase inhibitor (GSI) Com-
pound E to interfere with NOTCH1 processing and
assayed NANOG expression levels. We observed a 10-
fold decrease in NANOG protein levels in the GSI-trea-
ted cells (Figure 4E), suggesting that NANOG may be
NOTCH1-regulated in mouse and human breast cancer
cells. Although conserved CSL sites were found in the
mouse and human NANOG regulatory regions, we were
unable to detect intracellular NOTCH1 binding to the
mouse Nanog regulatory region, suggesting that
NOTCH1 may indirectly regulate Nanog expression
(data not shown).
NOTCH1-induced mammary tumors consist of a mix of
luminal progenitors and mature luminal cells
Mammary tumors derived from MMTV-Wnt-1,
MMTV-Neu, and p53+/- mice exhibit uniform Lin-
CD29loCD24+ cell-surface marker profiles, but differ in
CD61 cell-surface expression levels [52]. These findings,
in conjunction with the differences seen between devel-
oping mammary glands in NOTCH1 transgenic mice
and wild-type littermates (Figure 1), led us to hypothe-
size that NOTCH1-induced mammary tumors might
express a distinct luminal surface-marker profile. Analy-
sis of CD24 and CD29 surface-marker expression on the
lineage-negative population of NOTCH1 mammary
tumor cells revealed expression of a luminal cell profile
(Lin-CD24+CD29lo), compared with wild-type mammary
cells (Figure 5A and 5B). When the Lin-CD24+CD29lo
population is further analyzed for CD61 expression, we
find that these mammary tumors do not appear to
express CD61 (Figure 5B). Interestingly, when we ana-
lyzed tumor-derived cell lines 8542 and 8526 with flow
cytometry, we found that the two cell lines are com-
posed almost exclusively of luminal cells, but that unlike
the primary tumor, the cell lines consist predominantly
of CD61-positive cells (Figure 5B, C). Based on these
data, we hypothesized that CD61+ cells are present at
low frequency in the primary mammary tumors. Consis-
tent with this hypothesis, CD61+ cells can be readily
detected when primary mammary tumors are cultured
under tumorsphere conditions (Figure 5D). These data
indicate that the NOTCH1-induced mammary tumors
are composed of a mixed population of luminal progeni-
tors and mature luminal cells, and that conversion to
culture selects for the luminal progenitors.
NOTCH1 inhibition results in mammary tumor regression
and delays disease recurrence
Previous studies suggest that human breast cancer cells
become dependent on NOTCH1 in the absence of ERa
or ERB2 signaling [15,18,20], raising the possibility that
NOTCH inhibition may have therapeutic potential in
TN human basal-like breast cancers. To determine
whether NOTCH1 activity is required to maintain mam-
mary tumor growth and survival in vivo, we adminis-
tered doxycycline to tumor-bearing MMTV-tTA/TOP-
ICN1 mice. Exposure to doxycycline to suppress intra-
cellular NOTCH1 expression resulted in a 55% decrease
in average tumor volume after 48 hours, and a >90%
decrease in average tumor volume by day 9 (Figure 6A).
To confirm that NOTCH1 signaling is impaired in
regressing tumors, we isolated RNA from tumor-bearing
mice left untreated or treated with doxycycline. Real-
time quantitative PCR analysis revealed decreases in
Hes1, Deltex1, and c-Myc expression levels in tumors
isolated from dox-treated mice compared with untreated
controls, thereby confirming repression of NOTCH1
signaling in the dox-treated mammary tumor-bearing
mice (Figure 6B).
To determine whether NOTCH1 inhibition interferes
with or prevents disease recurrence, we treated six
tumor-bearing mice with doxycycline for 28 days, and
then removed dox from the drinking water and moni-
tored the animals for disease recurrence. Tumor
regrowth was observed within 40 days of dox withdrawal
in two of six tumor-bearing mice (Figure 6C). However,
disease was not detected in the remaining four dox-trea-
ted mammary tumor-bearing mice, indicating that
NOTCH1 inhibition was sufficient to prevent disease
recurrence in these mice.
Mammary tumor-initiating cells contribute to NOTCH1-
mediated mammary tumorigenesis
Accumulating evidence suggests that certain tumors
exhibit functional heterogeneity and that tumor initia-
tion may be driven by a subset of cells designated
tumor-initiating or tumor stem cells [53]. With a novel
orthotopic mouse model, progress has been made in
identifying a breast cancer stem or initiating population
from TN breast cancer patients [54]. To determine
whether NOTCH1-mediated mammary tumorigenesis is
driven by a rare tumor-initiating cell, we performed an
in vivo limiting-dilution assay. Four independent
NOTCH1-driven mouse mammary tumors were injected
as serial dilutions into the thoracic mammary fat pad of
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immunodeficient mice, and recipient mice were monitored
for disease development. The frequency of mammary
tumor-initiating cells was calculated by using the software
program L-Calc (StemCell Technologies, Vancouver,
Canada) and estimated to be 1/2,978 cells [95% confidence
interval (95% CI), 1/5,689 to 1/1,559] (Table 1). This ana-
lysis revealed that the mammary tumor-initiating cell in
this mammary tumor model is relatively rare and that the
bulk of the NOTCH1-transformed mammary tumor cells
lack the capacity to initiate disease in immunodeficient
recipient mice.
NOTCH1 mediates tumorsphere colony activity in vitro
{2nd level heading}
Our studies using doxycycline to suppress NOTCH1
activity in tumor-bearing mice suggest that NOTCH1
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Figure 5 NOTCH1-transformed mammary tumors consist of mature luminal and luminal progenitor cells. (A) MMVT-tTA/TOP-ICN1
tumors and tumor cell lines are derived from luminal cells. Representative FACS profiles (n = 3) showing the expression of CD29 and CD24 in
the CD45-CD31-Ter119- (Lin-) population of the wild-type mammary gland, NOTCH1-transformed mammary tumor, or mammary tumor-derived
cell line 8542. (B) Primary tumors consist of mature luminal cells, whereas tumor-derived cell lines consist of luminal progenitors. Representative
histogram showing the CD61 expression levels within the Lin-CD29loCD24+ luminal cell populations shown in (A). Dashed line, staining observed
with isotype-matched negative control. (C, D) Tumorsphere culture of primary NOTCH1-transformed mammary tumors enriches for CD61+ cells.
Tumor-derived cell lines (C) or primary mammary tumor cells (D) or were grown under tumorsphere conditions for 7 days, centrifuged onto
slides, and stained with an isotype-matched control or anti-CD61-FITC antibody. Representative fields are shown at 400 × magnification (isotype
control is shown in inset). Scale bars, 100 μm.
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inhibition prevents or, at a minimum, delays disease
recurrence (Figure 6C). We then tested whether
NOTCH1 activity was required for mammary tumor-
initiating cell activity by using an in vitro tumorsphere
assay [38,55]. Tumorsphere-forming cells increase after
neoadjuvant chemotherapy, and the molecular profile of
tumors obtained after chemotherapy resembles the gene-
expression profile of tumorsphere cells, suggesting that
this assay enriches for tumor-initiating cells [56,57]. Pri-
mary NOTCH1-transformed mammary tumor cells
formed spheres in culture at a rate of 1 in 268 (0.37%)
(Figure 7A). Importantly, the ability of these cells to form
tumorspheres in vitro remains dependent on the expres-
sion of intracellular NOTCH1, as treatment of primary
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Figure 6 NOTCH1 inhibition results in mammary tumor regression in vivo and reduces tumorsphere activity in vitro. (A) NOTCH1
inhibition in vivo results in rapid mammary tumor regression. Tumor-bearing mice (n = 5) were treated with doxycycline (10 μg/ml) for 11 days,
and tumor volume was monitored externally by using calipers. The graph shows average tumor volume over time and standard error.
(B) Doxycycline treatment results in decreased NOTCH1 target-gene expression. Total RNA was harvested from mammary tumors isolated from
mice left untreated or treated with doxycycline (10 μg/ml) for 24 or 48 hours. Hes1, Deltex1, and c-Myc expression levels were quantified by
using real-time quantitative PCR. Results were plotted relative to untreated levels. (C) NOTCH1 inhibition in vivo interferes with disease
recurrence. Tumor-bearing MMTV-tTA/TOP-ICN1 transgenic mice were administered water containing doxycycline (10 μg/ml) for 28 days, and
tumor volume was monitored externally by using calipers. Doxycycline was then removed from the water, and mice were monitored for tumor
regrowth for an additional 40 days. Mice that failed to exhibit tumor regrowth were then killed and examined histologically for the presence of
residual mammary tumor cells.
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mammary tumor cells with doxycycline results in a >75%
decrease in the number of tumorspheres (Figure 7A, and
see Additional file 5; P < 0.0001). The tumorspheres
appeared enriched in Notch1-active cells, as Deltex1
expression was increased in the spheres compared with
the primary tumors from which they were derived (Addi-
tional File 5). The tumorspheres that did emerge in the
dox-treated cultures were noticeably smaller and less
defined in structure than were the cultures in which
intracellular NOTCH1 remained expressed (Figure 7B).
Together, these data suggest that NOTCH1 contributes
to mammary tumor-initiating activity in vitro and poten-
tially in vivo.
Discussion
Notch1 has been shown to promote commitment of
mouse mammary stem cells along the luminal lineage
[25,58]. Consistent with these and other studies
[26,31-33], we show that constitutive expression of intra-
cellular NOTCH1 in the developing mouse mammary
gland stimulates luminal fate, ultimately resulting in
transformation of the mammary gland. The mammary
tumors predominantly express the luminal lineage mar-
ker keratin 8/18. Interestingly, in our model expression
of human intracellular NOTCH1 in the developing
mouse mammary gland did not result in induction of
diverse tumor types that regressed upon weaning. Nor
did the transgenic females exhibit any difficulty nursing
their young. This is in contrast to transgenic models that
constitutively express mouse ICN1 driven by the Mouse
Mammary Tumor Virus (MMTV) LTR. These mice are
unable to nurse their young and they develop lactation-
dependent papillary tumors that regress upon involution
[31,32]. The reasons for the phenotypic differences could
reflect transgene expression levels or the timing of trans-
gene induction since our model is doxycycline-regulated.
Alternatively, human ICN1 may not interact with a
mouse co-factor essential for lactation.
Using an in vivo limiting-dilution assay, we provide
evidence that NOTCH1-transformed mammary tumors
Table 1 Limiting-dilution analysis of primary MMTV-tTA/TOP-ICN1 tumor cells
Number ofinjected cells Number of micedeveloping tumors Average latency(days)
106 4/4 15.75 (± 3.5)
105 7/7 20 (± 6.3)
104 11/12 42 (± 13.6)
103 6/14 43 (± 11.2)
102 0/10 >100
Repopulating frequency (95% confidence interval), 1 in 2,978 (1/5,689 to 1/1,559).
Number of positive outgrowths is shown as the number of mice developing tumors per the number of mice injected. Serial dilutions of primary tumor cells were
resuspended in Matrigel, transplanted into the thoracic mammary fat pads of nude mice; transplanted mice were monitored for disease. Data are pooled from
four independent mammary tumors. Tumor-repopulating frequency was calculated by using L-Calc limiting-dilution analysis software.
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Figure 7 NOTCH1 inhibition reduces mammary tumorsphere formation. (A) Quantification of tumorsphere-forming potential of primary
tumor cells isolated from dissociated MMTV-tTA/TOP-ICN1 tumors left untreated or treated with doxycycline (2 μg/ml) for 8 days. Error bars
denote standard error (n = 3). (B) Representative images of untreated and doxycycline-treated mammary tumorspheres showing relative
difference in tumorsphere size and morphology. Examples of spheres that were counted are indicated with arrows.
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are functionally heterogeneous and estimate the fre-
quency of mammary tumor-initiating cells to be
approximately 1/3000 cells. We demonstrate that doxy-
cycline treatment or NOTCH1 inhibition in vivo pre-
vents disease recurrence in 4 of 6 mice examined.
However, disease recurred within 21 days in 2 tumor
bearing mice treated with dox, suggesting that
NOTCH1 inhibition in these tumors was not sufficient
to eliminate the tumor-initiating cells. These relapsed
mammary tumors may contain increased numbers of
mammary tumor-initiating cells and/or harbor genetic
changes that render the tumors NOTCH1 independent.
Consistent with the in vivo limiting-dilution analyses,
a subpopulation of NOTCH1 transformed mammary
tumor cells grow in an in vitro tumorsphere assay and
importantly, doxycycline treatment significantly reduces
sphere number and size. The tumorsphere assays
revealed that NOTCH1 is required both for the initia-
tion and maintenance of tumorspheres in vitro and
potentially for mammary tumor-initiating activity in
vivo.
GSI treatment of ERB2-induced mouse mammary
tumors reduced tumorspheres in vitro and interfered
with the ability of the mammary tumor-initiating cells
to induce disease in immunodeficient mice [59]. These
studies are consistent with our findings and collectively
suggest that NOTCH inhibitors may target mammary
tumor-initiating cells driven by other oncogenes and not
be limited to mammary tumors that exhibit NOTCH
pathway activation.
NOTCH pathway activation has also been implicated
in human mammary tumor-initiating cell biology. GSI
treatment or treatment with an anti-NOTCH4 monoclo-
nal antibody significantly reduces human tumorsphere
formation in vitro [60]. Studies in the human breast
cancer cell lines MCF7 and MDA-MB-231 show that
NOTCH1 or NOTCH4 silencing reduces tumorsphere
formation and inhibits tumor growth in vivo; however,
NOTCH4 suppression appears to have the greatest inhi-
bitory effect [61]. Thus, its possible that NOTCH4 is the
relevant NOTCH receptor in human breast cancer-initi-
ating cells.
To identify NOTCH1-regulated genes that might
mediate mammary tumor-initiating cell activity, we
applied transcriptional profiling to two mammary tumor
cell lines in the absence/presence of doxycycline. We
found the expression of several NOTCH1-regulated
genes such as Hes1, Hey1, Deltex1 and c-Myc signifi-
cantly reduced upon doxycycline treatment. In addition
to these target genes, NOTCH1 activation stimulates
expression of embryonic stem (ES) cell pluripotency
transcription factor Nanog. The Nanog-Oct4-Sox2
(NOS) transcription factors activate self-renewal and
inhibit differentiation in human and mouse ES cells and
the NOS signature is enriched in claudin-low and basal-
like breast cancer subtypes [62-64]. Consistent with
these findings, we show that treatment of the ER-nega-
tive, basal-like human breast cancer cell line MDA-MB-
231 with a gamma-secretase inhibitor reduces intracellu-
lar NOTCH1 and NANOG protein levels.
Like CD61, Nanog expression was not detected in the
primary mouse mammary tumor tissue but was readily
observed in the nuclei of the CD61-positive mammary
tumor cell lines and tumorspheres. These data suggest
that NOTCH1 regulation of Nanog may be cell-type or
developmental stage specific. Thus, NOTCH1 may
induce Nanog expression in luminal progenitors and
mammary tumor-initiating cells but not in the bulk dif-
ferentiated tumor cells. Although CSL sites are present
in the mouse Nanog regulatory region, we were unable
to demonstrate NOTCH1 or Mastermind-like 1 recruit-
ment to the mouse Nanog locus, leading us to speculate
that NOTCH1 may indirectly regulate Nanog expression
in mammary tumor- initiating cells. Consistent with this
hypothesis, ChIP-seq analysis has suggested that
NOTCH1 binds the genome in association with the zinc
finger protein ZNF143 [65] and Nanog expression in
mouse ES cells has been linked to Znf143 regulation
[66]. Thus, Notch1 and Znf143 may co-regulate Nanog
expression in mammary tumor-initiating cells. Consis-
tent with our findings in the mouse, siRNA studies have
demonstrated that OCT4 and NANOG expression are
required for human breast tumor-initiating activity [62].
Conclusions
The relative resistance of breast cancer stem cells to
conventional and targeted therapies highlights the need
to develop agents able to target this population. Our
findings in this NOTCH1 mammary tumor model
implicate NOTCH1 as a potential therapeutic target in
breast tumor-initiating cells.
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Additional file 1: Nulliparous MMTV-tTa/TOP-ICN1 mice express
increased levels of intracellular NOTCH1 compared with littermate
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Additional file 2: NOTCH1 activity does not significantly alter CD61
expression levels. Mammary tumor cell lines were left untreated or
were treated with doxycycline (2 μg/ml) for 24 hours. Total RNA was
harvested and CD61, Hes1, and Deltex1 mRNA levels determined using
quantitative real-time PCR. The figure represents an average of two
independent cell lines.
Additional file 3: Nulliparous MMTV-tTA/TOP-ICN1 transgenic mice
develop mammary tumors after a long latency. A cohort of
nulliparous MMTV-tTA/TOP-ICN1 mice (n = 14) and littermate controls (n
= 15) were monitored for tumor formation and compared with cohorts
of MMTV-tTA/TOP-ICN1 transgenic mice (n = 65) maintained under
mating conditions. The proportion of tumor-free mice was plotted by
using the Kaplan-Meier software.
Additional file 4: Mammary tumor-derived cell lines produce
tumors morphologically identical to primary tumors. Tumor-derived
cell lines were injected into the mammary fat pads of nude mice, and
the resulting tumors were fixed in 10% formalin, paraffin embedded,
sectioned and stained with hematoxylin and eosin (H&E). Representative
fields are shown at 400X magnification.
Additional file 5: Mammary tumorspheres are enriched in NOTCH1
activity and remain doxycycline responsive. Primary mammary tumor
cells were plated in the tumorsphere assay and were left untreated or
were treated with 2 μg/ml doxycycline for 24 hours. Total RNA was
harvested from pooled spheres, and Deltex1 mRNA levels were
determined using quantitative real-time PCR. The figure represents the
average from two independent experiments and was normalized to
primary tumor RNA.
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